QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.059394v1 308/3/1197    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chavkin, C. Articles by Roth, B. L. Search for Related Content PubMed PubMed Citation Articles by Chavkin, C. Articles by Roth, B. L.

NEUROPHARMACOLOGY

Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious -Opioid Receptor Agonist: Structural and Functional Considerations

Department of Pharmacology, University of Washington School of Medicine, Seattle, Washington (C.C., S.S., W.J.); Salvia divinorum Research and Information Center, Los Angeles, California (D.S.); Department of Pharmacognosy, University of Mississippi, Oxford, Mississippi (J.S., J.K.Z.); and National Institute of Mental Health Psychoactive Drug Screening Program and Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, Ohio (B.A.T., S.J.H., B.L.R.)

The diterpene salvinorin A from Salvia divinorum has recently been reported to be a high-affinity and selective -opioid receptor agonist (Roth et al., 2002). Salvinorin A and selected derivatives were found to be potent and efficacious agonists in several measures of agonist activity using cloned human -opioid receptors expressed in human embryonic kidney-293 cells. Thus, salvinorin A, salvinorinyl-2-propionate, and salvinorinyl-2-heptanoate were found to be either full (salvinorin A) or partial (2-propionate, 2-heptanoate) agonists for inhibition of forskolin-stimulated cAMP production. Additional studies of agonist potency and efficacy of salvinorin A, performed by cotransfecting either the chimeric G proteins Gaq-i5 or the universal G protein Ga16 and quantification of agonist-evoked intracellular calcium mobilization, affirmed that salvinorin A was a potent and effective -opioid agonist. Results from structure-function studies suggested that the nature of the substituent at the 2-position of salvinorin A was critical for -opioid receptor binding and activation. Because issues of receptor reserve complicate estimates of agonist efficacy and potency, we also examined the agonist actions of salvinorin A by measuring potassium conductance through G protein-gated K⁺ channels coexpressed in Xenopus oocytes, a system in which receptor reserve is minimal. Salvinorin A was found to be a full agonist, being significantly more efficacious than (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide methane-sulfonate hydrate (U50488) or (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide methane-sulfonate hydrate (U69593) (two standard -opioid agonists) and similar in efficacy to dynorphin A (the naturally occurring peptide ligand for -opioid receptors). Salvinorin A thus represents the first known naturally occurring non-nitrogenous full agonist at -opioid receptors.

Address correspondence to: Dr. Bryan Roth, Department of Biochemistry; Room RT500-9, Case Western Reserve University Medical School, 2109 Adelbert Rd., Cleveland, OH 44106. E-mail: roth{at}biocserver.cwru.edu

This article has been cited by other articles:

				Y. Wang, Y. Chen, W. Xu, D. Y.W. Lee, Z. Ma, S. M. Rawls, A. Cowan, and L.-Y. Liu-Chen 2-Methoxymethyl-Salvinorin B Is a Potent {kappa} Opioid Receptor Agonist with Longer Lasting Action in Vivo Than Salvinorin A J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1073 - 1083. [Abstract] [Full Text] [PDF]

				C. Beguin, D. N. Potter, J. A. DiNieri, T. A. Munro, M. R. Richards, T. A. Paine, L. Berry, Z. Zhao, B. L. Roth, W. Xu, et al. N-Methylacetamide Analog of Salvinorin A: A Highly Potent and Selective {kappa}-Opioid Receptor Agonist with Oral Efficacy J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 188 - 195. [Abstract] [Full Text] [PDF]

				T. A. Vortherms, P. D. Mosier, R. B. Westkaemper, and B. L. Roth Differential Helical Orientations among Related G Protein-coupled Receptors Provide a Novel Mechanism for Selectivity: STUDIES WITH SALVINORIN A AND THE {kappa}-OPIOID RECEPTOR J. Biol. Chem., February 2, 2007; 282(5): 3146 - 3156. [Abstract] [Full Text] [PDF]

				C. E. Groer, K. Tidgewell, R. A. Moyer, W. W. Harding, R. B. Rothman, T. E. Prisinzano, and L. M. Bohn An Opioid Agonist that Does Not Induce {micro}-Opioid Receptor--Arrestin Interactions or Receptor Internalization Mol. Pharmacol., February 1, 2007; 71(2): 549 - 557. [Abstract] [Full Text] [PDF]

				E. R. Butelman, M. Mandau, K. Tidgewell, T. E. Prisinzano, V. Yuferov, and M. J. Kreek Effects of Salvinorin A, a {kappa}-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High {kappa}-Receptor Homology to Humans J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 300 - 306. [Abstract] [Full Text] [PDF]

				T. A. Vortherms and B. L. Roth Salvinorin a: from natural product to human therapeutics. Mol. Interv., October 1, 2006; 6(5): 257 - 265. [Abstract] [Full Text] [PDF]

				M. A. Ansonoff, J. Zhang, T. Czyzyk, R. B. Rothman, J. Stewart, H. Xu, J. Zjwiony, D. J. Siebert, F. Yang, B. L. Roth, et al. Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of {kappa}-Opioid Receptor-1 Knockout Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 641 - 648. [Abstract] [Full Text] [PDF]

				W. K. Kroeze and B. L. Roth Screening the receptorome. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 41 - 46. [Abstract] [PDF]

				M. R. Bruchas, T. A. Macey, J. D. Lowe, and C. Chavkin Kappa Opioid Receptor Activation of p38 MAPK Is GRK3- and Arrestin-dependent in Neurons and Astrocytes J. Biol. Chem., June 30, 2006; 281(26): 18081 - 18089. [Abstract] [Full Text] [PDF]

				W. A. Carlezon Jr., C. Beguin, J. A. DiNieri, M. H. Baumann, M. R. Richards, M. S. Todtenkopf, R. B. Rothman, Z. Ma, D. Y.-W. Lee, and B. M. Cohen Depressive-Like Effects of the {kappa}-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 440 - 447. [Abstract] [Full Text] [PDF]

				Y. Wang, K. Tang, S. Inan, D. Siebert, U. Holzgrabe, D. Y.W. Lee, P. Huang, J.-G. Li, A. Cowan, and L.-Y. Liu-Chen Comparison of Pharmacological Activities of Three Distinct {kappa} Ligands (Salvinorin A, TRK-820 and 3FLB) on {kappa} Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 220 - 230. [Abstract] [Full Text] [PDF]

				D. J. SIEBERT Localization of Salvinorin A and Related Compounds in Glandular Trichomes of the Psychoactive Sage, Salvia divinorum Ann. Bot., June 1, 2004; 93(6): 763 - 771. [Abstract] [Full Text] [PDF]